A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

BACKGROUND: This open-label, phase 1 trial (NCT02316197) aimed to determine the maximum-tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of peposertib (formerly M3814), a DNA-dependent protein kinase (DNA-PK) inhibitor in patients with advanced solid tumours. Secondary/exploratory objecti...

Descripción completa

Detalles Bibliográficos
Autores principales: van Bussel, Mark T. J., Awada, Ahmad, de Jonge, Maja J. A., Mau-Sørensen, Morten, Nielsen, Dorte, Schöffski, Patrick, Verheul, Henk M. W., Sarholz, Barbara, Berghoff, Karin, El Bawab, Samer, Kuipers, Mirjam, Damstrup, Lars, Diaz-Padilla, Ivan, Schellens, Jan H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884679/
https://www.ncbi.nlm.nih.gov/pubmed/33230210
http://dx.doi.org/10.1038/s41416-020-01151-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884679/
https://www.ncbi.nlm.nih.gov/pubmed/33230210
http://dx.doi.org/10.1038/s41416-020-01151-6

Ejemplares similares